Cipher Pharmaceuticals (TSE:CPH) has released an update.
Cipher Pharmaceuticals has expanded its portfolio with the acquisition of Natroba™, a high-performing dermatology product from ParaPRO, for US$89.5 million. The deal includes the product rights and a seasoned commercial sales team, positioning Cipher for significant market growth in North America and globally. Natroba™, a highly effective treatment for head lice and scabies, is expected to strengthen Cipher’s presence in the dermatology sector.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
